We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.22 | -0.75% | 160.50 | 162.44 | 158.12 | 162.31 | 5,941,930 | 23:04:33 |
From May 2019 to May 2024
By Allison Prang
AbbVie Inc. turned a second-quarter loss as Allergan acquisition-related costs hurt results.
AbbVie's loss was $738 million, or 46 cents a share. In the second quarter of 2019, AbbVie had a profit of $741 million, or 49 cents a share.
Adjusted earnings were $2.34 a share. According to FactSet, analysts were expecting $2.20 a share.
Net revenue increased 26% to $10.43 billion, including a partial quarter for Allergan. Analysts guided for $9.94 billion.
Operating costs and expenses about doubled. Acquisition-related costs hurt earnings per share by $1.08.
The company closed the deal to buy Allergan in May.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
July 31, 2020 08:17 ET (12:17 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
